drugset / Trial / NCT00043888
Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR
RandomizedParallel-groupOpen-labelTreatment
Summary
Antiretroviral Therapy (ART) naive subjects will be enrolled in this clinical research study to test the safety and tolerability of fosamprenavir with or without ritonavir in combination TRIZIVIR and COMBIVIR. Subjects will receive 24 weeks of therapy.
Timeline
- Start
- 2002-01
- Primary completion
- 2003-05
- Completion
- 2003-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fosamprenavir | Small molecule | 700 mg | — |
| Subject | Fosamprenavir | Small molecule | 1400 mg | — |
| Subject | Lamivudine | Other / unclassified | — | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | Trizivir | Unknown | — | — |